MedTrace Logo

Treatment Of Hot Flashes/Flushes In Postmenopausal Women (WARM Study)

NCT00604825 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 356

Last updated 2017-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether GSK232802 is safe and effective in reducing the frequency and severity of hot flashes associated with menopause.

Conditions

  • Menopausal and Female Climacteric States

Interventions

DRUG

Other: Placebo

DRUG

GSK232802

DRUG

PREMARIN

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-17
Primary Completion
2008-07-23
Completion
2008-07-23

Countries

  • United States
  • Argentina
  • Australia
  • Germany
  • Italy
  • New Zealand
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604825 on ClinicalTrials.gov